BMS-779788

BMS-779788 is a small molecule, investigational drug developed by Bristol Myers Squibb as a partial agonist of the liver X receptor (LXR), with selectivity for the LXRβ isoform. It was designed to induce expression of genes involved in reverse cholesterol transport, such as ABCA1 and ABCG1, while minimizing lipogenic side effects typically associated with full LXR agonists. In preclinical studies in cynomolgus monkeys and mice, BMS-779788 demonstrated comparable efficacy to full agonists in stimulating target gene expression but showed reduced elevation of plasma triglycerides and LDL cholesterol. The compound reached phase 1 clinical trials for safety evaluation in healthy subjects but development was terminated due to neurological or psychiatric side effects observed during dosing.

Other names

918348-67-1